SL-701 - Revision history

Lazy at 08:27, 18 January 2025

2025-01-18T08:27:57Z

← Older revision		Revision as of 01:27, 18 January 2025
Line 23:		Line 23:
	\|links=https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v61/7405736, https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi51/6426882, https://www.targetedonc.com/view/sl-701-demonstrates-antitumor-activity-in-relapsed-refractory-gbm		\|links=https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v61/7405736, https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi51/6426882, https://www.targetedonc.com/view/sl-701-demonstrates-antitumor-activity-in-relapsed-refractory-gbm

	}}		\|overview=SL-701 is an investigational immunotherapy vaccine currently in Phase II clinical trials for treating relapsed or refractory Glioblastoma Multiforme (GBM), showing promising median overall survival rates above historical controls while exhibiting a manageable safety profile with mild to moderate side effects. Although not yet FDA-approved, the vaccine's ability to elicit specific immune responses against GBM antigens underscores its potential as a novel treatment strategy.}}

Lazy at 13:50, 25 December 2024

2024-12-25T13:50:13Z

← Older revision		Revision as of 06:50, 25 December 2024
Line 22:		Line 22:
	in a phase I/II trial for HLA-A2 positive recurrent glioblastoma.		in a phase I/II trial for HLA-A2 positive recurrent glioblastoma.
	\|links=https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v61/7405736, https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi51/6426882, https://www.targetedonc.com/view/sl-701-demonstrates-antitumor-activity-in-relapsed-refractory-gbm		\|links=https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v61/7405736, https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi51/6426882, https://www.targetedonc.com/view/sl-701-demonstrates-antitumor-activity-in-relapsed-refractory-gbm
	~~\|treatment_category=Tumor-associated antigen vaccines~~

	}}		}}

Lazy at 13:47, 25 December 2024

2024-12-25T13:47:30Z

← Older revision		Revision as of 06:47, 25 December 2024
Line 9:		Line 9:
	\|PFS_without=Not specified		\|PFS_without=Not specified
	\|PFS_with=Data on progression-free survival specifically for SL-701 is under investigation; significant antitumor activity has been noted.		\|PFS_with=Data on progression-free survival specifically for SL-701 is under investigation; significant antitumor activity has been noted.
			\|treatment_category=Vaccines
	\|usefulness_rating=4		\|usefulness_rating=4
	\|usefulness_explanation=SL-701 shows promise in extending overall survival and inducing long-term survival in a subset of patients, particularly those with target-specific CD8+ T cell responses. The vaccine's ability to elicit specific immune responses against GBM antigens underscores its potential as a novel treatment strategy.		\|usefulness_explanation=SL-701 shows promise in extending overall survival and inducing long-term survival in a subset of patients, particularly those with target-specific CD8+ T cell responses. The vaccine's ability to elicit specific immune responses against GBM antigens underscores its potential as a novel treatment strategy.

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:44:36Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:44, 12 November 2024
Line 21:		Line 21:
	in a phase I/II trial for HLA-A2 positive recurrent glioblastoma.		in a phase I/II trial for HLA-A2 positive recurrent glioblastoma.
	\|links=https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v61/7405736, https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi51/6426882, https://www.targetedonc.com/view/sl-701-demonstrates-antitumor-activity-in-relapsed-refractory-gbm		\|links=https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v61/7405736, https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi51/6426882, https://www.targetedonc.com/view/sl-701-demonstrates-antitumor-activity-in-relapsed-refractory-gbm
	\|~~category~~=Tumor-associated antigen vaccines		\|treatment_category=Tumor-associated antigen vaccines

	}}		}}

Lazy at 21:32, 31 March 2024

2024-03-31T21:32:53Z

← Older revision		Revision as of 14:32, 31 March 2024
Line 21:		Line 21:
	in a phase I/II trial for HLA-A2 positive recurrent glioblastoma.		in a phase I/II trial for HLA-A2 positive recurrent glioblastoma.
	\|links=https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v61/7405736, https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi51/6426882, https://www.targetedonc.com/view/sl-701-demonstrates-antitumor-activity-in-relapsed-refractory-gbm		\|links=https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v61/7405736, https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi51/6426882, https://www.targetedonc.com/view/sl-701-demonstrates-antitumor-activity-in-relapsed-refractory-gbm
			\|category=Tumor-associated antigen vaccines

	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=SL-701 (Immunotherapy Vaccine) |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Relapsed or refractory Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II |common_side_effects=Fatigue, injection site reaction, erythema, and pain were the most common treatment-related adverse events. No grade 4/5 adverse events reported, indicating a manageable safety profile. |OS_without=Historical controls suggest a median overall surv..."

2024-03-31T21:14:55Z

Created page with "{{TreatmentInfo |drug_name=SL-701 (Immunotherapy Vaccine) |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Relapsed or refractory Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II |common_side_effects=Fatigue, injection site reaction, erythema, and pain were the most common treatment-related adverse events. No grade 4/5 adverse events reported, indicating a manageable safety profile. |OS_without=Historical controls suggest a median overall surv..."

New page

{{TreatmentInfo
|drug_name=SL-701 (Immunotherapy Vaccine)
|FDA_approval=In clinical trials; not yet FDA-approved
|used_for=Relapsed or refractory Glioblastoma Multiforme (GBM)
|clinical_trial_phase=Phase II
|common_side_effects=Fatigue, injection site reaction, erythema, and pain were the most common treatment-related adverse events. No grade 4/5 adverse events reported, indicating a manageable safety profile.
|OS_without=Historical controls suggest a median overall survival of 20-35% at 12 months for similar populations.
|OS_with=Stage 1 median overall survival was 11.0 months with a 12-month OS rate of 44%. Stage 2 showed a median OS of 11.7 months with a 12-month OS rate of 50%, suggesting an improvement over historical data.
|PFS_without=Not specified
|PFS_with=Data on progression-free survival specifically for SL-701 is under investigation; significant antitumor activity has been noted.
|usefulness_rating=4
|usefulness_explanation=SL-701 shows promise in extending overall survival and inducing long-term survival in a subset of patients, particularly those with target-specific CD8+ T cell responses. The vaccine's ability to elicit specific immune responses against GBM antigens underscores its potential as a novel treatment strategy.
|toxicity_level=2
|toxicity_explanation=The vaccine's safety profile is characterized by the absence of severe adverse events, with only mild to moderate reactions observed, making it a potentially safer option for GBM treatment.
|book_text=A similar approach has been used by Dr. Hideho Okada and colleagues at the University
of Pittsburgh. In a pilot study using this approach with patients with recurrent tumors
(162) several major tumor responses were observed. Median survival for the 13 GBM
patients in the trial was 12 months, with several of the patients still progression-free at the
time of the report. A later version of this therapy, called SL-701, consists of three
shortened peptides corresponding to glioma-associated antigens and is now being tested
in a phase I/II trial for HLA-A2 positive recurrent glioblastoma.
|links=https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v61/7405736, https://academic.oup.com/neuro-oncology/article/23/Supplement_6/vi51/6426882, https://www.targetedonc.com/view/sl-701-demonstrates-antitumor-activity-in-relapsed-refractory-gbm
}}